Alpine Immune Sciences, Inc. (ALPN) News

Alpine Immune Sciences, Inc. (ALPN): $64.97

0.01 (+0.02%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add ALPN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#269 of 360

in industry

Filter ALPN News Items

ALPN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALPN News Highlights

  • For ALPN, its 30 day story count is now at 7.
  • Over the past 15 days, the trend for ALPN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ALPN are LYRA, AUPH and CRBP.

Latest ALPN News From Around the Web

Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie

SEATTLE, December 21, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept.

Yahoo | December 21, 2023

Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?

Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.

Yahoo | December 19, 2023

Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, December 18, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30 am PT/10:30 am ET, and the Company will participate in one-on-one investor meetings.

Yahoo | December 18, 2023

Optimistic Investors Push Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Up 41% But Growth Is Lacking

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...

Yahoo | December 18, 2023

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Yahoo | December 12, 2023

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Yahoo | December 11, 2023

Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High?

The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 56.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 6, 2023

Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?

Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Yahoo | November 29, 2023

Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference

SEATTLE, November 20, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the upcoming Evercore ISI HealthconX Conference, November 28-30, 2023.

Yahoo | November 20, 2023

Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 79.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 20, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!